

Fabio Marra

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1738853/publications.pdf>

Version: 2024-02-01

283
papers

22,246
citations

7069

78
h-index

10127

140
g-index

286
all docs

286
docs citations

286
times ranked

23223
citing authors

#	ARTICLE	IF	CITATIONS
1	An Alternatively Spliced Variant of CXCR3 Mediates the Inhibition of Endothelial Cell Growth Induced by IP-10, Mig, and I-TAC, and Acts as Functional Receptor for Platelet Factor 4. <i>Journal of Experimental Medicine</i> , 2003, 197, 1537-1549.	4.2	655
2	NASH limits anti-tumour surveillance in immunotherapy-treated HCC. <i>Nature</i> , 2021, 592, 450-456.	13.7	649
3	Acute viral hepatitis increases liver stiffness values measured by transient elastography. <i>Hepatology</i> , 2008, 47, 380-384.	3.6	643
4	Roles for Chemokines in Liver Disease. <i>Gastroenterology</i> , 2014, 147, 577-594.e1.	0.6	634
5	Liver stiffness measurement predicts severe portal hypertension in patients with HCV-related cirrhosis. <i>Hepatology</i> , 2007, 45, 1290-1297.	3.6	628
6	Lipotoxicity and the gut-liver axis in NASH pathogenesis. <i>Journal of Hepatology</i> , 2018, 68, 280-295.	1.8	566
7	Differential effect of oleic and palmitic acid on lipid accumulation and apoptosis in cultured hepatocytes. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2009, 24, 830-840.	1.4	467
8	Clinical patterns of hepatocellular carcinoma in nonalcoholic fatty liver disease: A multicenter prospective study. <i>Hepatology</i> , 2016, 63, 827-838.	3.6	467
9	Concomitant Activation of the JAK/STAT, PI3K/AKT, and ERK Signaling Is Involved in Leptin-Mediated Promotion of Invasion and Migration of Hepatocellular Carcinoma Cells. <i>Cancer Research</i> , 2007, 67, 2497-2507.	0.4	430
10	Adipokines in liver diseases. <i>Hepatology</i> , 2009, 50, 957-969.	3.6	410
11	Cytokine Receptors and Signaling in Hepatic Stellate Cells. <i>Seminars in Liver Disease</i> , 2001, 21, 397-416.	1.8	397
12	Ligands of peroxisome proliferator-activated receptor β modulate profibrogenic and proinflammatory actions in hepatic stellate cells. <i>Gastroenterology</i> , 2000, 119, 466-478.	0.6	390
13	Genome-wide meta-analyses identify three loci associated with primary biliary cirrhosis. <i>Nature Genetics</i> , 2010, 42, 658-660.	9.4	389
14	Molecular basis and mechanisms of progression of non-alcoholic steatohepatitis. <i>Trends in Molecular Medicine</i> , 2008, 14, 72-81.	3.5	381
15	Increased risk of cardiovascular disease in non-alcoholic fatty liver disease: causal effect or epiphenomenon?. <i>Diabetologia</i> , 2008, 51, 1947-1953.	2.9	374
16	Accuracy and reproducibility of transient elastography for the diagnosis of fibrosis in pediatric nonalcoholic steatohepatitis. <i>Hepatology</i> , 2008, 48, 442-448.	3.6	351
17	Upregulation of proinflammatory and proangiogenic cytokines by leptin in human hepatic stellate cells. <i>Hepatology</i> , 2005, 42, 1339-1348.	3.6	310
18	HNE interacts directly with JNK isoforms in human hepatic stellate cells.. <i>Journal of Clinical Investigation</i> , 1998, 102, 1942-1950.	3.9	280

#	ARTICLE	IF	CITATIONS
19	Signal Transduction by the Chemokine Receptor CXCR3. <i>Journal of Biological Chemistry</i> , 2001, 276, 9945-9954.	1.6	272
20	AISF position paper on nonalcoholic fatty liver disease (NAFLD): Updates and future directions. <i>Digestive and Liver Disease</i> , 2017, 49, 471-483.	0.4	254
21	Monocyte chemotactic protein-1 as a chemoattractant for human hepatic stellate cells. <i>Hepatology</i> , 1999, 29, 140-148.	3.6	253
22	CD14+CD34low Cells With Stem Cell Phenotypic and Functional Features Are the Major Source of Circulating Endothelial Progenitors. <i>Circulation Research</i> , 2005, 97, 314-322.	2.0	245
23	International genome-wide meta-analysis identifies new primary biliary cirrhosis risk loci and targetable pathogenic pathways. <i>Nature Communications</i> , 2015, 6, 8019.	5.8	245
24	Reliability of transient elastography for the diagnosis of advanced fibrosis in chronic hepatitis C. <i>Gut</i> , 2008, 57, 1288-1293.	6.1	242
25	Signal transduction in hepatic stellate cells. <i>Liver</i> , 1998, 18, 2-13.	0.1	209
26	Transcriptomic profiling across the nonalcoholic fatty liver disease spectrum reveals gene signatures for steatohepatitis and fibrosis. <i>Science Translational Medicine</i> , 2020, 12, .	5.8	205
27	Behavior therapy for nonalcoholic fatty liver disease: The need for a multidisciplinary approach. <i>Hepatology</i> , 2008, 47, 746-754.	3.6	204
28	Practice guidelines for the diagnosis and management of nonalcoholic fatty liver disease. <i>Digestive and Liver Disease</i> , 2010, 42, 272-282.	0.4	202
29	Phosphatidylinositol 3-kinase is required for platelet-derived growth factor's actions on hepatic stellate cells. <i>Gastroenterology</i> , 1997, 112, 1297-1306.	0.6	199
30	Proangiogenic Cytokines as Hypoxia-Dependent Factors Stimulating Migration of Human Hepatic Stellate Cells. <i>American Journal of Pathology</i> , 2007, 170, 1942-1953.	1.9	196
31	Silybin, a component of sylimarin, exerts anti-inflammatory and anti-fibrogenic effects on human hepatic stellate cells. <i>Journal of Hepatology</i> , 2009, 50, 1102-1111.	1.8	186
32	Cultured human liver fat-storing cells produce monocyte chemotactic protein-1. Regulation by proinflammatory cytokines. <i>Journal of Clinical Investigation</i> , 1993, 92, 1674-1680.	3.9	182
33	The PNPLA3 I148M variant modulates the fibrogenic phenotype of human hepatic stellate cells. <i>Hepatology</i> , 2017, 65, 1875-1890.	3.6	177
34	Improved noninvasive prediction of liver fibrosis by liver stiffness measurement in patients with nonalcoholic fatty liver disease accounting for controlled attenuation parameter values. <i>Hepatology</i> , 2017, 65, 1145-1155.	3.6	177
35	Extracellular signal-regulated kinase activation differentially regulates platelet-derived growth factor's actions in hepatic stellate cells, and is induced by <i>In Vivo</i> liver injury in the rat. <i>Hepatology</i> , 1999, 30, 951-958.	3.6	161
36	Liver stiffness is influenced by a standardized meal in patients with chronic hepatitis C virus at different stages of fibrotic evolution. <i>Hepatology</i> , 2013, 58, 65-72.	3.6	159

#	ARTICLE	IF	CITATIONS
37	Myofibroblast "like cells and liver fibrogenesis: Emerging concepts in a rapidly moving scenario. <i>Molecular Aspects of Medicine</i> , 2008, 29, 58-66.	2.7	153
38	Technology Insight: noninvasive assessment of liver fibrosis by biochemical scores and elastography. <i>Nature Reviews Gastroenterology & Hepatology</i> , 2008, 5, 95-106.	1.7	151
39	Molecular Pathogenesis of NASH. <i>International Journal of Molecular Sciences</i> , 2016, 17, 1575.	1.8	150
40	Diagnostic accuracy of elastography and magnetic resonance imaging in patients with NAFLD: A systematic review and meta-analysis. <i>Journal of Hepatology</i> , 2021, 75, 770-785.	1.8	149
41	Hepatic stellate cells and the regulation of liver inflammation. <i>Journal of Hepatology</i> , 1999, 31, 1106-1119.	1.8	146
42	Chemokines in liver inflammation and fibrosis. <i>Frontiers in Bioscience - Landmark</i> , 2002, 7, d1899-1914.	3.0	145
43	Extracellular Signal-Regulated Kinases Modulate Capacitation of Human Spermatozoa. <i>Biology of Reproduction</i> , 1998, 58, 1476-1489.	1.2	143
44	Overexpression of Bcl-2 by activated human hepatic stellate cells: resistance to apoptosis as a mechanism of progressive hepatic fibrogenesis in humans. <i>Gut</i> , 2005, 55, 1174-1182.	6.1	143
45	Resistin as an Intrahepatic Cytokine. <i>American Journal of Pathology</i> , 2006, 169, 2042-2053.	1.9	142
46	The chemokine CCL21 modulates lymphocyte recruitment and fibrosis in chronic hepatitis C. The authors thank Wanda Delogu and Nadia Navari for skillful technical help, Dr. Roberto G. Romanelli for help in collecting liver biopsy specimens, and Dr. Mario Strazzabosco (Ospedali Riuniti di Bergamo, Italy) for help in collecting liver biopsy specimens. <i>Gut</i> , 2006, 55, 1060-1076.	0.6	140
47	Pathophysiology of NASH: Perspectives for a Targeted Treatment. <i>Current Pharmaceutical Design</i> , 2013, 19, 5250-5269.	0.9	140
48	Challenges of advanced hepatocellular carcinoma. <i>World Journal of Gastroenterology</i> , 2016, 22, 7645.	1.4	135
49	gp120 modulates the biology of human hepatic stellate cells: a link between HIV infection and liver fibrogenesis. <i>Gut</i> , 2010, 59, 513-520.	6.1	124
50	Expression of platelet-derived growth factor in newly formed cholangiocytes during experimental biliary fibrosis in rats. <i>Journal of Hepatology</i> , 1999, 31, 100-109.	1.8	122
51	Human leukocyte antigen polymorphisms in italian primary biliary cirrhosis: A multicenter study of 664 patients and 1992 healthy controls. <i>Hepatology</i> , 2008, 48, 1906-1912.	3.6	120
52	Adenosine monophosphate-activated protein kinase modulates the activated phenotype of hepatic stellate cells. <i>Hepatology</i> , 2008, 47, 668-676.	3.6	118
53	Refining the Baveno VI elastography criteria for the definition of compensated advanced chronic liver disease. <i>Journal of Hepatology</i> , 2021, 74, 1109-1116.	1.8	112
54	Interferon-inducible protein 10, monokine induced by interferon gamma, and interferon-inducible T-cell alpha chemoattractant are produced by thymic epithelial cells and attract T-cell receptor (TCR) $\alpha\beta$ ⁺ CD8 ⁺ single-positive T cells, TCR $\alpha\beta$ ⁺ T cells, and natural killer "type cells in human thymus. <i>Blood</i> , 2001, 97, 601-607.	0.6	111

#	ARTICLE	IF	CITATIONS
55	Validity criteria for the diagnosis of fatty liver by M probe-based controlled attenuation parameter. <i>Journal of Hepatology</i> , 2017, 67, 577-584.	1.8	110
56	Intracellular reactive oxygen species are required for directional migration of resident and bone marrow-derived hepatic pro-fibrogenic cells. <i>Journal of Hepatology</i> , 2011, 54, 964-974.	1.8	109
57	Nitrovasodilators inhibit platelet-derived growth factor-induced proliferation and migration of activated human hepatic stellate cells. <i>Gastroenterology</i> , 2000, 119, 479-492.	0.6	108
58	LMW-PTP Is a Negative Regulator of Insulin-Mediated Mitotic and Metabolic Signalling. <i>Biochemical and Biophysical Research Communications</i> , 1997, 238, 676-682.	1.0	106
59	MERTK rs4374383 polymorphism affects the severity of fibrosis in non-alcoholic fatty liver disease. <i>Journal of Hepatology</i> , 2016, 64, 682-690.	1.8	106
60	Evidence for a storage pool defect in platelets from cirrhotic patients with defective aggregation. <i>Gastroenterology</i> , 1992, 103, 641-646.	0.6	105
61	4-Hydroxynonenal as a selective pro-fibrogenic stimulus for activated human hepatic stellate cells. <i>Journal of Hepatology</i> , 2004, 40, 60-68.	1.8	103
62	Pretreatment prediction of response to ursodeoxycholic acid in primary biliary cholangitis: development and validation of the UDCA Response Score. <i>The Lancet Gastroenterology and Hepatology</i> , 2018, 3, 626-634.	3.7	103
63	The role of adipokines in liver fibrosis. <i>Pathophysiology</i> , 2008, 15, 91-101.	1.0	102
64	Up-regulated expression of fractalkine and its receptor CX3CR1 during liver injury in humans. <i>Journal of Hepatology</i> , 2002, 37, 39-47.	1.8	97
65	Thrombin stimulates proliferation of liver fat-storing cells and expression of monocyte chemotactic protein-1: Potential role in liver injury. <i>Hepatology</i> , 1995, 22, 780-787.	3.6	96
66	Expression of the thrombin receptor in human liver: Up-regulation during acute and chronic injury. <i>Hepatology</i> , 1998, 27, 462-471.	3.6	95
67	Prevention of severe toxic liver injury and oxidative stress in MCP-1-deficient mice. <i>Journal of Hepatology</i> , 2007, 46, 230-238.	1.8	93
68	Patients with advanced hepatocellular carcinoma need a personalized management: A lesson from clinical practice. <i>Hepatology</i> , 2018, 67, 1784-1796.	3.6	93
69	Increased phosphorylation of AKAP by inhibition of phosphatidylinositol 3-kinase enhances human sperm motility through tail recruitment of protein kinase A. <i>Journal of Cell Science</i> , 2004, 117, 1235-1246.	1.2	92
70	Transforming growth factor- β 1 regulates platelet-derived growth factor receptor β 2 subunit in human liver fat-storing cells. <i>Hepatology</i> , 1995, 21, 232-239.	3.6	90
71	Under-dilated TIPS Associate With Efficacy and Reduced Encephalopathy in a Prospective, Non-randomized Study of Patients With Cirrhosis. <i>Clinical Gastroenterology and Hepatology</i> , 2018, 16, 1153-1162.e7.	2.4	90
72	Effects of low-dose captopril on renal hemodynamics and function in patients with cirrhosis of the liver. <i>Gastroenterology</i> , 1993, 104, 588-594.	0.6	87

#	ARTICLE	IF	CITATIONS
73	Efficacy and safety of the stepped care medical treatment of ascites in liver cirrhosis: a randomized controlled clinical trial comparing two diets with different sodium content. <i>Liver</i> , 1993, 13, 156-162.	0.1	87
74	Involvement of phosphatidylinositol 3-kinase in the activation of extracellular signal-regulated kinase by PDGF in hepatic stellate cells. <i>FEBS Letters</i> , 1995, 376, 141-145.	1.3	85
75	Leptin and liver fibrosis: A matter of fat. <i>Gastroenterology</i> , 2002, 122, 1529-1532.	0.6	85
76	Curcumin limits the fibrogenic evolution of experimental steatohepatitis. <i>Laboratory Investigation</i> , 2010, 90, 104-115.	1.7	84
77	Mononuclear cells in liver fibrosis. <i>Seminars in Immunopathology</i> , 2009, 31, 345-358.	2.8	83
78	Hepatic decompensation is the major driver of death in HCV-infected cirrhotic patients with successfully treated early hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2017, 67, 65-71.	1.8	83
79	Role of the stromal-derived factor-1 (SDF-1)â€“CXCR4 axis in the interaction between hepatic stellate cells and cholangiocarcinoma. <i>Journal of Hepatology</i> , 2012, 57, 813-820.	1.8	82
80	Dendrosomal curcumin nanoformulation downregulates pluripotency genes via miR-145 activation in U87MG glioblastoma cells. <i>International Journal of Nanomedicine</i> , 2014, 9, 403.	3.3	79
81	Plasma levels of brain natriuretic peptide in patients with cirrhosis. <i>Hepatology</i> , 1992, 16, 156-161.	3.6	78
82	Dose dependent and divergent effects of superoxide anion on cell death, proliferation, and migration of activated human hepatic stellate cells. <i>Gut</i> , 2006, 55, 90-97.	6.1	78
83	Oxidative stress parameters in paediatric non-alcoholic fatty liver disease. <i>International Journal of Molecular Medicine</i> , 2010, 26, 471-6.	1.8	78
84	Interferon-gamma-mediated activation of STAT1alpha regulates growth factor-induced mitogenesis.. <i>Journal of Clinical Investigation</i> , 1996, 98, 1218-1230.	3.9	76
85	Chemokines in liver inflammation and fibrosis. <i>Frontiers in Bioscience - Landmark</i> , 2002, 7, d1899.	3.0	75
86	Cellular and Molecular Mechanisms Underlying Liver Fibrosis Regression. <i>Cells</i> , 2021, 10, 2759.	1.8	73
87	The Src and Signal Transducers and Activators of Transcription Pathways As Specific Targets for Low Molecular Weight Phosphotyrosine-protein Phosphatase in Platelet-derived Growth Factor Signaling. <i>Journal of Biological Chemistry</i> , 1998, 273, 6776-6785.	1.6	72
88	Phosphatidylinositol-3 kinase and extracellular signal-regulated kinase mediate the chemotactic and mitogenic effects of insulin-like growth factor-I in human hepatic stellate cells. <i>Journal of Hepatology</i> , 2000, 32, 227-234.	1.8	71
89	The biphasic nature of hypoxiaâ€“induced directional migration of activated human hepatic stellate cells. <i>Journal of Pathology</i> , 2012, 226, 588-597.	2.1	71
90	Agonist-specific regulation of monocyte chemoattractant protein-1 expression by cyclooxygenase metabolites in hepatic stellate cells. <i>Hepatology</i> , 2001, 33, 713-721.	3.6	69

#	ARTICLE	IF	CITATIONS
91	The changing scenario of hepatocellular carcinoma in Italy: an update. <i>Liver International</i> , 2021, 41, 585-597.	1.9	69
92	Renal hemodynamic and natriuretic effects of human atrial natriuretic factor infusion in cirrhosis with ascites. <i>Gastroenterology</i> , 1989, 96, 167-177.	0.6	67
93	The evolutionary scenario of hepatocellular carcinoma in Italy: an update. <i>Liver International</i> , 2017, 37, 259-270.	1.9	67
94	Fibrosis in alcoholic and nonalcoholic steatohepatitis. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2011, 25, 231-244.	1.0	63
95	Defective signal transduction in platelets from cirrhotics is associated with increased cyclic nucleotides. <i>Gastroenterology</i> , 1993, 105, 148-156.	0.6	62
96	Regulation of platelet-derived growth factor secretion and gene expression in human liver fat-storing cells. <i>Gastroenterology</i> , 1994, 107, 1110-1117.	0.6	62
97	An international genome-wide meta-analysis of primary biliary cholangitis: Novel risk loci and candidate drugs. <i>Journal of Hepatology</i> , 2021, 75, 572-581.	1.8	62
98	Interaction between 4-Hydroxy-2,3-alkenals and the Platelet-derived Growth Factor- β 2 Receptor. <i>Journal of Biological Chemistry</i> , 2000, 275, 40561-40567.	1.6	61
99	Activation of p38MAPK mediates the angiostatic effect of the chemokine receptor CXCR3-B. <i>International Journal of Biochemistry and Cell Biology</i> , 2008, 40, 1764-1774.	1.2	60
100	Fibrogenic signalling in hepatic stellate cells. <i>Journal of Hepatology</i> , 2010, 52, 949-950.	1.8	60
101	Mitochondrial oxidative metabolism contributes to a cancer stem cell phenotype in cholangiocarcinoma. <i>Journal of Hepatology</i> , 2021, 74, 1373-1385.	1.8	60
102	Induction of Procollagen Type I Gene Expression and Synthesis in Human Hepatic Stellate Cells by 4-Hydroxy-2,3-Nonenal and Other 4-Hydroxy-2,3-Alkenals Is Related to Their Molecular Structure. <i>Biochemical and Biophysical Research Communications</i> , 1996, 222, 261-264.	1.0	59
103	ERK5 differentially regulates PDGF-induced proliferation and migration of hepatic stellate cells. <i>Journal of Hepatology</i> , 2008, 48, 107-115.	1.8	59
104	Lack of CC chemokine ligand 2 differentially affects inflammation and fibrosis according to the genetic background in a murine model of steatohepatitis. <i>Clinical Science</i> , 2012, 123, 459-471.	1.8	59
105	c-Src Activates both STAT1 and STAT3 in PDGF-Stimulated NIH3T3 Cells. <i>Biochemical and Biophysical Research Communications</i> , 1997, 239, 493-497.	1.0	58
106	The mitogen-activated protein kinase ERK5 regulates the development and growth of hepatocellular carcinoma. <i>Gut</i> , 2015, 64, 1454-1465.	6.1	58
107	Clinical impact of sexual dimorphism in non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). <i>Liver International</i> , 2021, 41, 1713-1733.	1.9	58
108	Phosphatidylinositol 3-kinase inhibition enhances human sperm motility. <i>Human Reproduction</i> , 2001, 16, 1931-1937.	0.4	57

#	ARTICLE	IF	CITATIONS
109	Epidemiological trends and trajectories of MAFLD-associated hepatocellular carcinoma 2002â€“2033: the ITA.LI.CA database. <i>Gut</i> , 2023, 72, 141-152.	6.1	57
110	A â€œsystems medicineâ€ approach to the study of non-alcoholic fatty liver disease. <i>Digestive and Liver Disease</i> , 2016, 48, 333-342.	0.4	56
111	The Role of Stroma in Cholangiocarcinoma: The Intriguing Interplay between Fibroblastic Component, Immune Cell Subsets and Tumor Epithelium. <i>International Journal of Molecular Sciences</i> , 2018, 19, 2885.	1.8	53
112	Inhibition by pentoxifylline of extracellular signalâ€regulated kinase activation by plateletâ€derived growth factor in hepatic stellate cells. <i>British Journal of Pharmacology</i> , 1996, 119, 1117-1124.	2.7	52
113	Adipokines and Redox Signaling: Impact on Fatty Liver Disease. <i>Antioxidants and Redox Signaling</i> , 2011, 15, 461-483.	2.5	52
114	Difficulty with diagnosis of malignant pancreatic neoplasms coexisting with chronic pancreatitis. <i>World Journal of Gastroenterology</i> , 2005, 11, 5075.	1.4	52
115	Therapeutic and antilipoperoxidant effects of silybin-phosphatidylcholine complex in chronic liver disease: Preliminary results. <i>Current Therapeutic Research</i> , 1993, 53, 98-102.	0.5	50
116	Transjugular intrahepatic portosystemic shunt (TIPS): current indications and strategies to improve the outcomes. <i>Internal and Emergency Medicine</i> , 2020, 15, 37-48.	1.0	50
117	Molecular Mechanisms of Hepatic Fibrosis in Non-Alcoholic Steatohepatitis. <i>Digestive Diseases</i> , 2010, 28, 229-235.	0.8	49
118	Metabolic reprogramming in cholangiocarcinoma. <i>Journal of Hepatology</i> , 2022, 77, 849-864.	1.8	49
119	Longitudinal assessment of liver stiffness in patients undergoing antiviral treatment for hepatitis C. <i>Digestive and Liver Disease</i> , 2013, 45, 840-843.	0.4	47
120	Does malnutrition affect survival in cirrhosis?. <i>Hepatology</i> , 1996, 23, 1041-1046.	3.6	47
121	Antifibrogenic effects of canrenone, an antialdosteronic drug, on human hepatic stellate cells. <i>Gastroenterology</i> , 2003, 124, 504-520.	0.6	45
122	Metronomic capecitabine as second-line treatment for hepatocellular carcinoma after sorafenib discontinuation. <i>Journal of Cancer Research and Clinical Oncology</i> , 2018, 144, 403-414.	1.2	45
123	Comparison of the effects of torasemide and furosemide in nonazotemic cirrhotic patients with ascites: A randomized, double-blind study. <i>Hepatology</i> , 1991, 13, 1101-1105.	3.6	43
124	Biosynthesis of platelet-activating factor and its 1O-acyl analogue by liver fat-storing cells. <i>Gastroenterology</i> , 1994, 106, 1301-1311.	0.6	43
125	Elastography for the non-invasive assessment of liver disease: limitations and future developments. <i>Gut</i> , 2009, 58, 157-160.	6.1	41
126	Safety and efficacy of ruxolitinib in splanchnic vein thrombosis associated with myeloproliferative neoplasms. <i>American Journal of Hematology</i> , 2017, 92, 187-195.	2.0	41

#	ARTICLE	IF	CITATIONS
127	The concept of therapeutic hierarchy for patients with hepatocellular carcinoma: A multicenter cohort study. <i>Liver International</i> , 2019, 39, 1478-1489.	1.9	41
128	Differential requirement of members of the MAPK family for CCL2 expression by hepatic stellate cells. <i>American Journal of Physiology - Renal Physiology</i> , 2004, 287, G18-G26.	1.6	40
129	The inflammasome in liver disease. <i>Journal of Hepatology</i> , 2016, 65, 1055-1056.	1.8	40
130	ADMA correlates with portal pressure in patients with compensated cirrhosis. <i>European Journal of Clinical Investigation</i> , 2007, 37, 509-515.	1.7	39
131	Mammalian target of rapamycin mediates the angiogenic effects of leptin in human hepatic stellate cells. <i>American Journal of Physiology - Renal Physiology</i> , 2011, 301, G210-G219.	1.6	39
132	Liver stiffness correlates with methotrexate cumulative dose in patients with rheumatoid arthritis. <i>Digestive and Liver Disease</i> , 2012, 44, 149-153.	0.4	39
133	NLRP3 inflammasome as a target of berberine in experimental murine liver injury: interference with P2X7 signalling. <i>Clinical Science</i> , 2016, 130, 1793-1806.	1.8	39
134	The Influence of Iontophoresis on Acyclovir Transport and Accumulation in Rabbit Ear Skin. <i>Pharmaceutical Research</i> , 2005, 22, 1519-1524.	1.7	38
135	Utility of Tumor Burden Score to Stratify Prognosis of Patients with Hepatocellular Cancer: Results of 4759 Cases from ITA.LI.CA Study Group. <i>Journal of Gastrointestinal Surgery</i> , 2018, 22, 859-871.	0.9	38
136	Leptin and liver tissue repair: Do rodent models provide the answers?. <i>Journal of Hepatology</i> , 2007, 46, 12-18.	1.8	37
137	<i>In vitro</i> skin permeation and retention of parabens from cosmetic formulations. <i>International Journal of Cosmetic Science</i> , 2007, 29, 361-367.	1.2	37
138	Impaired superoxide anion, platelet-activating factor, and leukotriene B4 synthesis by neutrophils in cirrhosis. <i>Gastroenterology</i> , 1993, 105, 170-177.	0.6	36
139	Nonalcoholic fatty liver in nondiabetic patients with acute coronary syndromes. <i>European Journal of Clinical Investigation</i> , 2013, 43, 429-438.	1.7	36
140	The Metabolic Syndrome and Chronic Liver Disease. <i>Current Pharmaceutical Design</i> , 2014, 20, 5010-5024.	0.9	35
141	Defective aggregation in cirrhosis is independent of <i>in vivo</i> platelet activation. <i>Journal of Hepatology</i> , 1996, 24, 436-443.	1.8	34
142	Ang II Upregulation of the T-Lymphocyte Renin-Angiotensin System Is Amplified by Low-Grade Inflammation in Human Hypertension. <i>American Journal of Hypertension</i> , 2011, 24, 716-723.	1.0	34
143	Radiological Patterns of Lung Involvement in Inflammatory Bowel Disease. <i>Gastroenterology Research and Practice</i> , 2018, 2018, 1-10.	0.7	34
144	Myostatin regulates the fibrogenic phenotype of hepatic stellate cells via c-jun N-terminal kinase activation. <i>Digestive and Liver Disease</i> , 2019, 51, 1400-1408.	0.4	31

#	ARTICLE	IF	CITATIONS
145	Real-Life Clinical Data of Cabozantinib for Unresectable Hepatocellular Carcinoma. <i>Liver Cancer</i> , 2021, 10, 370-379.	4.2	31
146	Real-Life Clinical Data of Lenvatinib versus Sorafenib for Unresectable Hepatocellular Carcinoma in Italy. <i>Cancer Management and Research</i> , 2021, Volume 13, 9379-9389.	0.9	31
147	Characterization and regulation of the latent transforming growth factor- β^2 complex secreted by vascular pericytes. , 1996, 166, 537-546.		30
148	HIV-1 gp120 signaling through TLR4 modulates innate immune activation in human macrophages and the biology of hepatic stellate cells. <i>Journal of Leukocyte Biology</i> , 2016, 100, 599-606.	1.5	30
149	Measurement of Gamma Glutamyl Transferase to Determine Risk of Liver Transplantation or Death in Patients With Primary Biliary Cholangitis. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 1688-1697.e14.	2.4	30
150	Sex Steroids and Odorants Modulate Gonadotropin-Releasing Hormone Secretion in Primary Cultures of Human Olfactory Cells. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1999, 84, 4266-4273.	1.8	30
151	Bioadhesive monolayer film for the in vitro transdermal delivery of sumatriptan. <i>Journal of Pharmaceutical Sciences</i> , 2006, 95, 1561-1569.	1.6	29
152	Performance of Doppler ultrasound in the prediction of severe portal hypertension in hepatitis C virus-related chronic liver disease. <i>Liver International</i> , 2007, 27, 1379-1388.	1.9	29
153	Glycogenic hepatopathy associated with type 1 diabetes mellitus as a cause of recurrent liver damage. <i>Annals of Hepatology</i> , 2012, 11, 554-558.	0.6	29
154	Alcohol associated liver disease 2020: A clinical practice guideline by the Italian Association for the Study of the Liver (AISF). <i>Digestive and Liver Disease</i> , 2020, 52, 374-391.	0.4	29
155	PDGF stimulates tyrosine phosphorylation of JAK 1 protein tyrosine kinase in human mesangial cells. <i>Kidney International</i> , 1996, 49, 19-25.	2.6	28
156	MARCKS is a downstream effector in platelet-derived growth factor-induced cell motility in activated human hepatic stellate cells. <i>Experimental Cell Research</i> , 2008, 314, 1444-1454.	1.2	28
157	Role of Adipocytokines in Hepatic Fibrosis. <i>Current Pharmaceutical Design</i> , 2010, 16, 1929-1940.	0.9	28
158	CXCR3 and $\alpha 7$ integrin identify a subset of CD8+ mature thymocytes that share phenotypic and functional properties with CD8+ gut intraepithelial lymphocytes. <i>Gut</i> , 2006, 55, 961-968.	6.1	27
159	Modulation of Liver Fibrosis by Adipokines. <i>Digestive Diseases</i> , 2011, 29, 371-376.	0.8	27
160	Management strategies for hepatocellular carcinoma: old certainties and new realities. <i>Clinical and Experimental Medicine</i> , 2016, 16, 243-256.	1.9	27
161	The protein kinase CK2 contributes to the malignant phenotype of cholangiocarcinoma cells. <i>Oncogenesis</i> , 2019, 8, 61.	2.1	27
162	X Chromosome Contribution to the Genetic Architecture of Primary Biliary Cholangitis. <i>Gastroenterology</i> , 2021, 160, 2483-2495.e26.	0.6	27

#	ARTICLE	IF	CITATIONS
163	Effects of rhein on renal arachidonic acid metabolism and renal function in patients with congestive heart failure. <i>European Journal of Clinical Pharmacology</i> , 1989, 37, 1-5.	0.8	26
164	Torsemide in the treatment of patients with cirrhosis and ascites. <i>Cardiovascular Drugs and Therapy</i> , 1993, 7, 81-85.	1.3	26
165	Integrin-mediated stimulation of monocyte chemotactic protein-1 expression. <i>FEBS Letters</i> , 1997, 414, 221-225.	1.3	26
166	Renaming cytokines: MCP-1, Major Chemokine in Pancreatitis. <i>Gut</i> , 2005, 54, 1679-1681.	6.1	26
167	Restaging Patients With Hepatocellular Carcinoma Before Additional Treatment Decisions: A Multicenter Cohort Study. <i>Hepatology</i> , 2018, 68, 1232-1244.	3.6	26
168	PNPLA3 I148M Variant Impairs Liver X Receptor Signaling and Cholesterol Homeostasis in Human Hepatic Stellate Cells. <i>Hepatology Communications</i> , 2019, 3, 1191-1204.	2.0	26
169	<i>PCSK9</i> rs11591147 R46L loss-of-function variant protects against liver damage in individuals with NAFLD. <i>Liver International</i> , 2021, 41, 321-332.	1.9	26
170	Angiotensin II upregulates renin-angiotensin system in human isolated T lymphocytes. <i>Regulatory Peptides</i> , 2008, 151, 1-6.	1.9	24
171	Non-invasive assessment of liver fibrosis in patients with HBV-related chronic liver disease undergoing antiviral treatment: A preliminary study. <i>European Journal of Pharmacology</i> , 2017, 806, 105-109.	1.7	24
172	Epidermal growth factor, epidermal growth factor receptor, and transforming growth factor-alpha in human hyperplastic prostate tissue: expression and cellular localization. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1996, 81, 4148-4154.	1.8	24
173	Predictors of survival in patients with established cirrhosis and hepatocellular carcinoma treated with sorafenib. <i>World Journal of Gastroenterology</i> , 2014, 20, 786.	1.4	24
174	Effects of dietary supplementation with arachidonic acid on platelet and renal function in patients with cirrhosis. <i>Clinical Science</i> , 2004, 106, 27-34.	1.8	23
175	Evaluation of intracellular signalling pathways in response to insulin-like growth factor I in apoptotic-resistant activated human hepatic stellate cells. <i>Fibrogenesis and Tissue Repair</i> , 2009, 2, 1.	3.4	23
176	Development and Characterization of an Orodispersible Film for Vitamin D3 Supplementation. <i>Molecules</i> , 2020, 25, 5851.	1.7	23
177	Soluble CD163 and mannose receptor as markers of liver disease severity and prognosis in patients with primary biliary cholangitis. <i>Liver International</i> , 2020, 40, 1408-1414.	1.9	22
178	Pharmacokinetics and pharmacodynamics of torsemide and furosemide in patients with diuretic resistant ascites. <i>Journal of Hepatology</i> , 1996, 25, 481-490.	1.8	21
179	Nuclear factor- κ B inhibition and non-alcoholic steatohepatitis: inflammation as a target for therapy. <i>Gut</i> , 2008, 57, 570-572.	6.1	21
180	Overview of Prognostic Systems for Hepatocellular Carcinoma and ITA.LI.CA External Validation of MESH and CNLC Classifications. <i>Cancers</i> , 2021, 13, 1673.	1.7	21

#	ARTICLE	IF	CITATIONS
181	Increased serum miR-193a-5p during non-alcoholic fatty liver disease progression: Diagnostic and mechanistic relevance. <i>JHEP Reports</i> , 2022, 4, 100409.	2.6	20
182	Preneoplastic lesions in the liver: Molecular insights and relevance for clinical practice. <i>Liver International</i> , 2022, 42, 492-506.	1.9	20
183	Nuclear localization of TRK-A in liver cells. <i>Histology and Histopathology</i> , 2008, 23, 327-40.	0.5	20
184	Thrombopoietin stimulates migration and activates multiple signaling pathways in hepatoblastoma cells. <i>American Journal of Physiology - Renal Physiology</i> , 2006, 290, G120-G128.	1.6	19
185	A Nuclear Protein in Mesangial Cells That Binds to the Promoter Region of the Platelet-derived Growth Factor-A Chain Gene. <i>Journal of Biological Chemistry</i> , 1995, 270, 5541-5548.	1.6	18
186	Impact of psychosocial status on liver transplant process. <i>Annals of Hepatology</i> , 2019, 18, 804-809.	0.6	18
187	Pattern of macrovascular invasion in hepatocellular carcinoma. <i>European Journal of Clinical Investigation</i> , 2021, 51, e13542.	1.7	18
188	Thromboxane-receptor blockade increases water diuresis in cirrhotic patients with ascites. <i>Gastroenterology</i> , 1992, 103, 1017-1021.	0.6	17
189	n ω -3 polyunsaturated fatty acids worsen inflammation and fibrosis in experimental nonalcoholic steatohepatitis. <i>Liver International</i> , 2014, 34, 918-930.	1.9	17
190	Antitumor Activity of a Novel Fibroblast Growth Factor Receptor Inhibitor for Intrahepatic Cholangiocarcinoma. <i>American Journal of Pathology</i> , 2019, 189, 2090-2101.	1.9	17
191	Therapeutic application of stem cells in gastroenterology: An up-date. <i>World Journal of Gastroenterology</i> , 2011, 17, 3870.	1.4	17
192	Role of Myeloid-Epithelial-Reproductive Tyrosine Kinase and Macrophage Polarization in the Progression of Atherosclerotic Lesions Associated With Nonalcoholic Fatty Liver Disease. <i>Frontiers in Pharmacology</i> , 2019, 10, 604.	1.6	16
193	AQP3 is regulated by PPAR γ 3 and JNK in hepatic stellate cells carrying PNPLA3 I148M. <i>Scientific Reports</i> , 2017, 7, 14661.	1.6	15
194	The protease-inhibitor SerpinB3 as a critical modulator of the stem-like subset in human cholangiocarcinoma. <i>Liver International</i> , 2022, 42, 233-248.	1.9	15
195	Non-alcoholic fatty liver disease in adults 2021: A clinical practice guideline of the Italian Association for the Study of the Liver (AISF), the Italian Society of Diabetology (SID) and the Italian Society of Obesity (SIO). <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2022, 32, 1-16.	1.1	15
196	Targeting a phospho-STAT3-miRNAs pathway improves vesicular hepatic steatosis in an in vitro and in vivo model. <i>Scientific Reports</i> , 2018, 8, 13638.	1.6	14
197	CXCR7 contributes to the aggressive phenotype of cholangiocarcinoma cells. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2019, 1865, 2246-2256.	1.8	14
198	Guanosine 3 α :5 β -cyclic monophosphate-dependent pathway alterations in ventricular cardiomyocytes of spontaneously hypertensive rats. <i>British Journal of Pharmacology</i> , 2001, 134, 596-602.	2.7	13

#	ARTICLE	IF	CITATIONS
199	NASH: are genes blowing the hits?. <i>Journal of Hepatology</i> , 2004, 40, 853-856.	1.8	13
200	Role of Chemokines in the Biology of Cholangiocarcinoma. <i>Cancers</i> , 2020, 12, 2215.	1.7	13
201	Multifaceted Aspects of Metabolic Plasticity in Human Cholangiocarcinoma: An Overview of Current Perspectives. <i>Cells</i> , 2020, 9, 596.	1.8	13
202	Pre-transplant diabetes predicts atherosclerotic vascular events and cardiovascular mortality in liver transplant recipients: a long-term follow-up study. <i>European Journal of Internal Medicine</i> , 2020, 79, 70-75.	1.0	13
203	Treatment of Hepatocellular Carcinoma with Immune Checkpoint Inhibitors and Applicability of First-Line Atezolizumab/Bevacizumab in a Real-Life Setting. <i>Journal of Clinical Medicine</i> , 2021, 10, 3201.	1.0	13
204	Liver fibrosis in the context of nonalcoholic steatohepatitis: the role of adipokines. <i>Minerva Gastroenterology</i> , 2017, 64, 39-50.	0.3	13
205	Macrophage MerTK promotes profibrogenic cross-talk with hepatic stellate cells via soluble mediators. <i>JHEP Reports</i> , 2022, 4, 100444.	2.6	13
206	Effects of supplementation with unsaturated fatty acids on plasma and membrane lipid composition and platelet function in patients with cirrhosis and defective aggregation. <i>Journal of Hepatology</i> , 1998, 28, 654-661.	1.8	12
207	Thrombocytopenia in chronic liver disease: Lessons from transplanted patients. <i>Journal of Hepatology</i> , 2007, 47, 625-629.	1.8	12
208	Nonalcoholic steatohepatitis before and after liver transplant: keeping up with the times. <i>Expert Review of Gastroenterology and Hepatology</i> , 2019, 13, 173-178.	1.4	12
209	Measuring self-control across gender, age, language, and clinical status: A validation study of the Italian version of the Brief Self- Control Scale (BSCS). <i>PLoS ONE</i> , 2020, 15, e0237729.	1.1	12
210	Extracellular Signal-Regulated Kinase 5 Regulates the Malignant Phenotype of Cholangiocarcinoma Cells. <i>Hepatology</i> , 2021, 74, 2007-2020.	3.6	12
211	Evaluation of the prognostic value of liver stiffness in patients with hepatitis C virus treated with triple or dual antiviral therapy: A prospective pilot study. <i>World Journal of Gastroenterology</i> , 2015, 21, 3013.	1.4	12
212	Oncostatin M is overexpressed in NASH-related hepatocellular carcinoma and promotes cancer cell invasiveness and angiogenesis. <i>Journal of Pathology</i> , 2022, 257, 82-95.	2.1	12
213	Non-alcoholic fatty liver disease in adults 2021: A clinical practice guideline of the Italian Association for the Study of the Liver (AISF), the Italian Society of Diabetology (SID) and the Italian Society of Obesity (SIO). <i>Digestive and Liver Disease</i> , 2022, 54, 170-182.	0.4	12
214	Hemostasis in chronic liver disease. <i>Journal of Thrombosis and Haemostasis</i> , 2006, 4, 2068-2069.	1.9	11
215	Effects of repeated atrial natriuretic peptide bolus injections in cirrhotic patients with refractory ascites. <i>Liver</i> , 1989, 9, 315-321.	0.1	11
216	Lack of nitric oxide- and guanosine 3',5'-cyclic monophosphate-dependent regulation of $\text{I}\kappa\text{B}$ -thrombin-induced calcium transient in endothelial cells of spontaneously hypertensive rat hearts. <i>British Journal of Pharmacology</i> , 2000, 130, 1468-1476.	2.7	10

#	ARTICLE	IF	CITATIONS
217	Thiazolidinediones and hepatic fibrosis: don't wait too long. <i>Gut</i> , 2006, 55, 917-919.	6.1	10
218	In vitro evaluation of the effect of electrotreatment on skin permeability. <i>Journal of Cosmetic Dermatology</i> , 2008, 7, 105-111.	0.8	10
219	Screening of distress among hospitalized patients in a department of internal medicine. <i>Asian Journal of Psychiatry</i> , 2015, 18, 91-96.	0.9	10
220	Hepatic Notch1 deletion predisposes to diabetes and steatosis via glucose-6-phosphatase and perilipin-5 upregulation. <i>Laboratory Investigation</i> , 2016, 96, 972-980.	1.7	10
221	Metabolic disorders across hepatocellular carcinoma in Italy. <i>Liver International</i> , 2018, 38, 2028-2039.	1.9	10
222	Monofocal hepatocellular carcinoma: How much does size matter?. <i>Liver International</i> , 2021, 41, 396-407.	1.9	10
223	The Role of the Hedgehog Pathway in Cholangiocarcinoma. <i>Cancers</i> , 2021, 13, 4774.	1.7	10
224	Ischemia-reperfusion: The liver under stress. <i>Hepatology</i> , 1997, 25, 1276-1278.	3.6	9
225	Amikacin reverse iontophoresis: Optimization of in vitro extraction. <i>International Journal of Pharmaceutics</i> , 2013, 440, 216-220.	2.6	9
226	Acute on chronic liver failure: From pathophysiology to clinical management. <i>Trends in Anaesthesia and Critical Care</i> , 2013, 3, 122-129.	0.4	9
227	Assessment of liver fibrosis in primary biliary cholangitis: Comparison between indirect serum markers and fibrosis morphometry. <i>Digestive and Liver Disease</i> , 2016, 48, 298-301.	0.4	9
228	Super-Resolution Microscopy Reveals an Altered Fibrin Network in Cirrhosis: The Key Role of Oxidative Stress in Fibrinogen Structural Modifications. <i>Antioxidants</i> , 2020, 9, 737.	2.2	9
229	Surveillance as Determinant of Long-Term Survival in Non-Transplanted Hepatocellular Carcinoma Patients. <i>Cancers</i> , 2021, 13, 897.	1.7	9
230	Rapid and sound assessment of well-being within a multi-dimensional approach: The Well-being Numerical Rating Scales (WB-NRSs). <i>PLoS ONE</i> , 2021, 16, e0252709.	1.1	9
231	Uncontrolled donation after circulatory death and liver transplantation: evidence and unresolved issues. <i>Minerva Anestesiologica</i> , 2020, 86, 196-204.	0.6	9
232	Complications of cirrhosis: is endothelium guilty?. <i>Journal of Hepatology</i> , 1999, 30, 532-535.	1.8	8
233	Synthesis, hydrolysis, and skin retention of amino acid esters of α -tocopherol. <i>Journal of Pharmaceutical Sciences</i> , 2009, 98, 2364-2376.	1.6	8
234	Metabolic Disorders After Liver Transplantation. <i>Metabolic Syndrome and Related Disorders</i> , 2021, 19, 65-69.	0.5	8

#	ARTICLE	IF	CITATIONS
235	Changes in hepatocellular carcinoma aggressiveness characteristics with an increase in tumor diameter. <i>International Journal of Biological Markers</i> , 2021, 36, 54-61.	0.7	8
236	Transient Hepatic Parenchymal Enhancement detected at dynamic imaging: A short instruction manual for the clinician. <i>Digestive and Liver Disease</i> , 2012, 44, 363-368.	0.4	7
237	Cytokine Production and Signaling in Stellate Cells. , 2015, , 63-86.		7
238	Liver Fibrosis and Leptin. <i>Current Pathobiology Reports</i> , 2016, 4, 69-76.	1.6	7
239	Sudden cardiac death in a patient with advanced hepatocellular carcinoma with good response to sorafenib treatment: A case report with literature analysis. <i>Molecular and Clinical Oncology</i> , 2017, 6, 389-396.	0.4	7
240	Comparison of prognostic models in advanced hepatocellular carcinoma patients undergoing Sorafenib: A multicenter study.. <i>Digestive and Liver Disease</i> , 2021, 53, 1011-1019.	0.4	7
241	Selective inhibition of NF- κ B in Kupffer cells: good, but not for everything. <i>Gut</i> , 2009, 58, 1581-1582.	6.1	6
242	Time-Varying mHAP-III Is the Most Accurate Predictor of Survival in Patients with Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization. <i>Liver Cancer</i> , 2021, 10, 126-136.	4.2	6
243	A Nomogram-Based Prognostic Model for Advanced Hepatocellular Carcinoma Patients Treated with Sorafenib: A Multicenter Study. <i>Cancers</i> , 2021, 13, 2677.	1.7	6
244	Lenvatinib: established and promising drug for the treatment of advanced hepatocellular carcinoma. <i>Expert Review of Clinical Pharmacology</i> , 2021, 14, 1353-1365.	1.3	6
245	Novel Aspects in the Pathogenesis of Nonalcoholic Steatohepatitis. <i>Current Molecular Medicine</i> , 2016, 16, 710-720.	0.6	6
246	Elevated plasma levels of urotensin II do not correlate with systemic haemodynamics in patients with cirrhosis. <i>Digestive and Liver Disease</i> , 2011, 43, 314-318.	0.4	5
247	Paradoxical embolization in TIPS: take a closer look to the heart. <i>Annals of Hepatology</i> , 2015, 14, 127-131.	0.6	4
248	Surveillance for hepatocellular carcinoma with a 3-months interval in "extremely high-risk" patients does not further improve survival. <i>Digestive and Liver Disease</i> , 2022, 54, 927-936.	0.4	4
249	A Phase 2 Study Of Ruxolitinib In Patients With Splanchnic Vein Thrombosis Associated With Myeloproliferative Neoplasm. Preliminary Results. <i>Blood</i> , 2013, 122, 1583-1583.	0.6	4
250	Material deprivation affects the management and clinical outcome of hepatocellular carcinoma in a high-resource environment. <i>European Journal of Cancer</i> , 2021, 158, 133-143.	1.3	4
251	Portosystemic shunt is an effective treatment for complications of portal hypertension in hepatic myeloid metaplasia and improves nutritional status. <i>Liver International</i> , 2022, 42, 419-424.	1.9	4
252	Predictors of solid extra-hepatic non-skin cancer in liver transplant recipients and analysis of survival: A long-term follow-up study. <i>Annals of Hepatology</i> , 2022, 27, 100683.	0.6	4

#	ARTICLE	IF	CITATIONS
253	Immunomodulation: a new approach to the therapy of cirrhosis?. Gut, 2010, 59, 868-869.	6.1	3
254	Cells in the Liver – Functions in Health and Disease. , 2011, , 3-32.		3
255	Characteristics and survival of patients with primary biliary cholangitis and hepatocellular carcinoma. Digestive and Liver Disease, 2022, 54, 1215-1221.	0.4	3
256	DNA Damage Response Inhibitors in Cholangiocarcinoma: Current Progress and Perspectives. Cells, 2022, 11, 1463.	1.8	3
257	Mechanisms of Fibrosis in Steatohepatitis. Current Hepatology Reports, 2014, 13, 142-150.	0.4	2
258	Aggressive Gastric Carcinoma Producing Alpha-Fetoprotein: A Case Report and Review of the Literature. Case Reports in Oncology, 2014, 7, 92-96.	0.3	2
259	A Large Rheumatoid Nodule Mimicking Hepatic Malignancy. Hepatology, 2019, 69, 1345-1348.	3.6	2
260	Statin-induced, immune-mediated injury with simultaneous targeting of skeletal muscle, skin and liver. Internal and Emergency Medicine, 2021, 16, 1719-1722.	1.0	2
261	Recalibrating survival prediction among patients receiving transarterial chemoembolization for hepatocellular carcinoma. Liver Cancer International, 2021, 2, 45-53.	0.2	2
262	From advanced disease to transplantation: an overview of the liver at the time of COVID-19 pandemic. Internal and Emergency Medicine, 2021, , 1.	1.0	2
263	Stellate Cells. , 2010, , 41-68.		2
264	Long Term Follow up of a Phase 2 Study of Ruxolitinib in Patients with Splanchnic Vein Thrombosis Associated with Myeloproliferative Neoplasm. Blood, 2015, 126, 2803-2803.	0.6	2
265	Oxidative Stress and Liver Fibrogenesis. Oxidative Stress in Applied Basic Research and Clinical Practice, 2015, , 171-196.	0.4	2
266	Alcohol use disorder and liver transplant: new perspectives and critical issues. Korean Journal of Internal Medicine, 2020, 35, 797-810.	0.7	2
267	Angiogenesis inhibitors for advanced hepatocellular carcinoma: in search for the right partner. Annals of Translational Medicine, 2020, 8, 1532-1532.	0.7	2
268	Paradoxical embolization in TIPS: take a closer look to the heart. Annals of Hepatology, 2015, 14, 127-31.	0.6	2
269	Ghrelin and fibrogenesis: Relief for a hungry liver. Journal of Hepatology, 2011, 55, 221-223.	1.8	1
270	Reply to – Genetic and clinical data reinforce the role of GAS6 and TAM receptors in liver fibrosis –™. Journal of Hepatology, 2016, 64, 984-985.	1.8	1

#	ARTICLE	IF	CITATIONS
271	Transjugular Intrahepatic Portosystemic Shunt does not affect the efficacy and safety of direct-acting antivirals in patients with advanced cirrhosis: A real-life, case-control study. Digestive and Liver Disease, 2019, 51, 870-874.	0.4	1
272	Stellate Cells. , 2005, , 27-44.		0
273	Cellular and molecular basis of fibrogenesis in NASH. Arab Journal of Gastroenterology, 2010, 10, S35-S37.	0.4	0
274	Hepatic brucellar abscess. Digestive and Liver Disease, 2013, 45, e15.	0.4	0
275	SALLuting a new biomarker in hepatocellular carcinoma. Annals of Hepatology, 2014, 13, 305-307.	0.6	0
276	Profibrogenic Actions of Hepatic Stellate Cells. , 2003, , 207-231.		0
277	The Cellular and Molecular Basis of Liver Fibrogenesis. , 1996, , 85-92.		0
278	Mechanisms of Fibrogenesis in NASH. , 2020, , 97-127.		0
279	Angiogenesis inhibitors for advanced hepatocellular carcinoma: in search for the right partner. Annals of Translational Medicine, 2020, 8, 1532.	0.7	0
280	Dynamics of endothelial progenitor cells in patients with advanced hepatocellular carcinoma. Digestive and Liver Disease, 2021, , .	0.4	0
281	Probiotics and the gut-liver axis. , 2022, , 467-481.		0
282	Quality of life in liver transplant recipients during the Corona virus disease 19 pandemic: A multicentre study. Liver International, 2022, 42, 1618-1628.	1.9	0
283	Biological therapies in patients with liver disease: are they really lifesavers?. Expert Opinion on Biological Therapy, 2022, 22, 473-490.	1.4	0